微型剂量胰高血糖素治疗1型糖尿病成人非严重低血糖的疗效与安全性
这项随机交叉试验在20名使用胰岛素泵和持续葡萄糖监测(CGM)的1型糖尿病成人中,比较非水性微型剂量胰高血糖素(MDG,150 µg)与葡萄糖片治疗非严重低血糖的效果。16名参与者共118次可分析事件中,MDG期62次事件有58次(94%)达标,葡萄糖片期56次事件有53次(95%)达标(校正P=0.99)。结论认为低剂量胰高血糖素可成功治疗轻度低血糖,在希望避免额外热量摄入时可能是有用的口服碳水化合物替代选择。
要点
- MDG期94%(58/62)与葡萄糖片期95%(53/56)事件达到成功治疗标准,校正P=0.99。
- 事件后2小时内CGM测得的范围内时间两组无差异,但葡萄糖片组第一小时最高血糖更高(116 vs 102 mg/dL;P=0.01)。
- 作者认为低剂量胰高血糖素可成功治疗轻度低血糖,可能是有用的口服碳水化合物替代选择。
核心结论
- 低剂量胰高血糖素可成功治疗轻度低血糖,在希望避免不必要热量摄入时可能是有用的口服碳水化合物替代选择。
研究设计与样本
- 随机交叉试验,包含两个为期3周的阶段;在美国5家糖尿病诊所开展;20名使用胰岛素泵和持续葡萄糖监测(CGM)且频繁发生轻度低血糖的1型糖尿病成人入组。
主要发现
- 16名参与者(平均年龄39岁,75%女性,平均糖尿病病程23年,平均糖化血红蛋白7.2%)共有118次可分析事件,初始血糖为50至69 mg/dL。
- MDG期62次事件中58次(94%)达到成功治疗标准,葡萄糖片期56次事件中53次(95%)达到成功治疗标准(校正P=0.99)。
- 上述事件的临床成功评估分别为97%和96%。
- 事件后2小时内CGM测得的范围内时间两组无差异,但葡萄糖片组第一小时最高血糖更高(116 vs 102 mg/dL;P=0.01)。
关键数值与推荐
- 成功治疗定义为研究血糖仪测得干预后15分钟血糖≥50 mg/dL且30分钟血糖≥70 mg/dL。
- 两名对治疗分组设盲的作者独立判断每次事件为临床成功或失败。
临床怎么用
- 作者认为低剂量胰高血糖素可成功治疗轻度低血糖,可能是有用的口服碳水化合物替代选择,用于希望避免不必要热量摄入时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Standard treatment of hypoglycemia is oral carbohydrate, but it often results in hyperglycemia and entails extra caloric intake. OBJECTIVE: To evaluate low-dose glucagon to treat mild hypoglycemia in ambulatory adults with type 1 diabetes (T1D). DESIGN: Randomized crossover trial (two 3-week periods). SETTING: Five U.S. diabetes clinics. PATIENTS: Twenty adults with T1D using an insulin pump and continuous glucose monitor (CGM) and experiencing frequent mild hypoglycemia. INTERVENTION: Nonaqueous mini-dose glucagon (MDG) (150 µg) to treat nonsevere hypoglycemia. MAIN OUTCOME MEASURES: Successful treatment was defined as blood glucose (BG) ≥50 mg/dL 15 minutes and ≥70 mg/dL 30 minutes after intervention, on the study meter. Two authors, blinded to treatment arm, independently judged each event as a clinical success or failure. RESULTS: Sixteen participants (mean age 39 years, 75% female, mean diabetes duration 23 years, mean hemoglobin A1c 7.2%) had 118 analyzable events with initial BG of 50 to 69 mg/dL. Successful treatment criteria were met for 58 (94%) of 62 events during the MDG period and 53 (95%) of 56 events during the glucose tablets (TABS) period (adjusted P = 0.99). Clinical assessments of success for these events were 97% and 96%, respectively. CGM-measured time in range did not differ between treatment groups during the 2 hours after events, but TABS resulted in higher maximum glucose (116 vs 102 mg/dL; P = 0.01) over the first hour. CONCLUSIONS: Low-dose glucagon can successfully treat mild hypoglycemia and may be a useful alternative to treatment with oral carbohydrate when trying to avoid unnecessary caloric intake.
引用
- Haymond MW, DuBose SN, Rickels MR, et al. Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes. J Clin Endocrinol Metab. 2017. PMID: 28591776. doi:10.1210/jc.2017-00591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。